Clinical Trials Directory

Trials / Completed

CompletedNCT03599531

Utility of the SomaLogic Cardiovascular Disease (CVD) Secondary Risk Panel for Cardiovascular Risk

A Pilot Study to Evaluate the Utility of the SomaLogic Cardiovascular Disease (CVD) Secondary Risk Panel as a a Tool to Stratify Cardiovascular Risk

Status
Completed
Phase
Study type
Observational
Enrollment
244 (actual)
Sponsor
SomaLogic, Inc. · Industry
Sex
All
Age
40 Years
Healthy volunteers
Not accepted

Summary

This is a prospective pilot study of participants who have stable coronary heart disease (CHD). Participants undergo risk stratification using the SomaLogic Cardiovascular Disease (CVD) Risk Panel blood test at baseline and again 4-12 months after the initial test. Participant surveys and chart abstractions are conducted at baseline and follow-up to collect feedback about the test report and actions taken. Care teams may consider using the risk information from the SomaLogic panel to address care gaps. Medical treatment decisions and recommendations are confirmed by established clinical methods, including blood pressure monitoring, body mass index (BMI), lipid and c-reactive protein (CRP) measurements, and physician's clinical judgment.

Detailed description

This is a prospective pilot study of participants who have stable coronary heart disease (CHD). Objectives of this study are to understand whether CVD Secondary Risk Panel scores change from baseline to follow-up (4-12 months after baseline) and actions taken, if any, based upon the results. Participants are surveyed to learn what the test results mean to them and assess if the results affect adherence to therapy and lifestyle choices (diet, exercise, alcohol, and tobacco use). In addition, this study will investigate the characteristics of patients that physicians choose to test with the CVD Secondary Risk Panel, and what actions the care team takes because of the results of the test. Medical treatment decisions and recommendations are confirmed by established clinical methods, including blood pressure monitoring, BMI, lipid and CRP measurements, and physician's clinical judgement. Chart abstractions and participants surveys occur at the baseline and follow-up visits, and charts may be abstracted annually for up to 10 years post enrollment.

Conditions

Timeline

Start date
2017-06-13
Primary completion
2020-10-10
Completion
2020-10-10
First posted
2018-07-26
Last updated
2021-03-17

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03599531. Inclusion in this directory is not an endorsement.